Fri, 26 May 2017 12:31:02: Safety profile will help bring ozanimod to multiple sclerosis market, says Celgene

Fri, 26 May 2017 09:36:34: Gottlieb ends FDA hiring freeze, lays out R&D priorities

Thu, 25 May 2017 19:47:01: Chutes & Ladders—Alexion’s C-suite overhaul involves CFO, R&D head

Thu, 25 May 2017 13:30:24: Harpoon Therapeutics hits $45M in series B for I-O work

Thu, 25 May 2017 13:06:19: NEJM paper buoys GW Pharma as it eyes FDA filing for cannabis drug Epidiolex

Thu, 25 May 2017 12:22:21: Months after trial setbacks, Merck licenses Teijin Alzheimer’s candidate

Thu, 25 May 2017 09:41:34: Redx stock suspended after loan repayment spat escalates

Thu, 25 May 2017 08:14:40: FDA panel backs Puma’s neratinib, clearing path to approval

Thu, 25 May 2017 07:42:50: WuXi Biologics guns for $500M Hong Kong IPO

Wed, 24 May 2017 13:33:21: Funding uncertainty could dent U.K.'s role as Euro biotech hub, says BIA

Wed, 24 May 2017 13:16:39: Takeda and NEA back $39M series A for GI biotech OrphoMed

Wed, 24 May 2017 12:54:13: ???????Cel-Sci, in trying to escape clinical hold, creates new problems for Multikine R&D program at the FDA

Wed, 24 May 2017 09:56:02: Pierre Fabre buys up Igenica preclinical I-O meds

Wed, 24 May 2017 08:35:19: Debiopharm buys ImmunoGen ADC to grow cancer pipeline

Tue, 23 May 2017 13:14:34: Cancer resistance firm TP Therapeutics reaps $45M in third round

Tue, 23 May 2017 12:34:06: Bioverativ to buy True North for $400M upfront

Tue, 23 May 2017 12:24:13: China’s CANbridge Life Sciences gains $25M series B, plots new cancer trials

Tue, 23 May 2017 10:56:21: Donald Trump’s healthcare budget outlines FDA, NIH cuts

Tue, 23 May 2017 09:10:29: Puma shares jump 40% after FDA review but brief leaves scope for AdComm grilling and neratinib rejection

Mon, 22 May 2017 13:20:10: Nektar pens sweetened Takeda cancer drugs deal

Mon, 22 May 2017 12:45:12: Celgene touts ozanimod MS data, but disability benefit weak over rival drug

Mon, 22 May 2017 12:39:38: Shock for Amgen and UCB as side effects undermine romo trial

Mon, 22 May 2017 12:05:34: Shire, Xenetic see hemophilia A candidate flunk key test

Mon, 22 May 2017 12:00:40: Merck KGaA, Ablynx push osteoarthritis asset toward clinic

Mon, 22 May 2017 09:11:59: La Jolla posts mixed bag of phase 3 data, raising hopes of FDA approval but calling commercial potential into question